首页> 外文OA文献 >A 2/1 sunitinib dosing schedule provides superior antitumor effectiveness and less toxicity than a 4/2 schedule for metastatic renal cell carcinoma: A systematic review and meta-analysis

【2h】

A 2/1 sunitinib dosing schedule provides superior antitumor effectiveness and less toxicity than a 4/2 schedule for metastatic renal cell carcinoma: A systematic review and meta-analysis

机译：2/1 Sunitinib给药时间表提供优异的抗肿瘤效果和比4/2转移性肾细胞癌的毒性更少：系统审查和荟萃分析

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Huan Deng; Lianli Zeng; Qian Wu; Li Wang; Zhengdong Hong; Fengming Yi; Yiping Wei; Wenxiong Zhang;
展开▼
作者单位

展开▼
年度 2019
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. A 2/1 Sunitinib Dosing Schedule Provides Superior Antitumor Effectiveness and Less Toxicity Than a 4/2 Schedule for Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-Analysis [J] . Huan Deng, Meng Li, Qian Wu, Frontiers in Oncology . 2020,第4期

机译：2/1 Sunitinib给药时间表提供优异的抗肿瘤效果和比4/2转移性肾细胞癌的毒性更少：系统审查和荟萃分析
2. Superior tolerability of altered dosing schedule of sunitinib with 2-weeks-on and 1-week-off in patients with metastatic renal cell carcinoma--comparison to standard dosing schedule of 4-weeks-on and 2-weeks-off. [J] . Tsunenori Kondo, Toshio Takagi, Hirohito Kobayashi, Japanese journal of clinical oncology. . 2014,第3期

机译：转移性肾细胞癌患者在2周和1周停用后改变舒尼替尼给药方案的耐受性较高-与4周和2周停用的标准给药方案相比具有更高的耐受性。
3. Safety and effectiveness of classical and alternative sunitinib dosing schedules for metastatic renal cell carcinoma: a meta-analysis [J] . Abogunrin Seye, Ashaye Ajibade O., Cappelleri Joseph C., Future oncology . 2019,第18期

机译：古典和替代Sunitinib剂量调速时间表的安全性和有效性，用于转移性肾细胞癌：META分析
4. When to Treat Metastatic Renal Cell Carcinoma Comorbidities, Systemic Therapy, and Active Surveillance in Metastatic Kidney Cancer [C] . Brian I. Rini Genitourinary Cancers Symposium . 2012

机译：何时治疗转移性肾细胞癌的组合，全身治疗，以及在转移性肾癌中的活跃监测
5. Renal Cell Carcinoma in End Stage Renal Disease Patients: An Institutional Review [D] . Nolte, Adam. 2019

机译：肾细胞癌在末期肾病患者：制度综述
6. A 2/1 Sunitinib Dosing Schedule Provides Superior Antitumor Effectiveness and Less Toxicity Than a 4/2 Schedule for Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-Analysis [O] . Huan Deng, Meng Li, Qian Wu, 2020

机译：2/1 Sunitinib给药时间表可提供比抗转移性肾细胞癌的4/2时间表更好的抗肿瘤效果和更低的毒性：系统评价和荟萃分析
7. PD39-09 DOES AN ALTERNATIVE SUNITINIB DOSING SCHEDULE REALLY IMPROVE SURVIVAL OUTCOMES OVER A CONVENTIONAL DOSING SCHEDULE IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA? AN UPDATED SYSTEMATIC REVIEW AND META-ANALYSIS [O] . Doo Yong Chung*, Beom-Yong Rho, Dong Hyuk Kang, 2020

机译：PD39-09是否有替代的Sunitinib给药计划在转移性肾细胞癌患者中，在常规给药方案中确实改善了存活结果？更新的系统审查和Meta分析

A 2/1 sunitinib dosing schedule provides superior antitumor effectiveness and less toxicity than a 4/2 schedule for metastatic renal cell carcinoma: A systematic review and meta-analysis

著录项

引文网络

相似文献

相关主题

期刊订阅